As a second‐generation of ALK‐TKI, ensartinib hold superior efficacy to crizotinib and had been approved for the first‐line treatment in patients with ALK‐positive nonsmall cell lung cancer (NSCLC) [3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.